Long-term observational study of sporadic inclusion body myositis. - Wikidata - wikimedia - TriplyDB

Long-term observational study of sporadic inclusion body myositis.

Long-term observational study of sporadic inclusion body myositis.

http://www.wikidata.org/entity/Q39698054

about

Treatment for inclusion body myositis Autoimmune Myopathies: Where Do We Stand?Idiopathic Inflammatory Myopathies: Clinical Approach and Management Emerging therapeutic options for sporadic inclusion body myositis Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies Update in inclusion body myositis Targeting protein homeostasis in sporadic inclusion body myositis.A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis?Immune and myodegenerative pathomechanisms in inclusion body myositis Stem cell transplantation for muscular dystrophy: the challenge of immune response.Ongoing developments in sporadic inclusion body myositis Sporadic inclusion body myositis: new insights and potential therapy.Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.Th1 response and systemic treg deficiency in inclusion body myositis.Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis.Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Expression of myogenic regulatory factors and myo-endothelial remodeling in sporadic inclusion body myositis Demographic and clinical features of inclusion body myositis in North America.A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Multicenter questionnaire survey for sporadic inclusion body myositis in Japan.Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA Update on treatment of inclusion body myositis.Diagnosis, pathogenesis and treatment of myositis: recent advances.Muscle diseases: mimics and chameleons.High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study.Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.Intravenous immunoglobulin in the treatment of neurologic disorders.Myositis Mimics.Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.A Systematic Review and Meta-Analysis of Prevalence Studies of Sporadic Inclusion Body Myositis.Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis.Diagnostic criteria for inclusion body myositis.Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.Predictors of Reduced Health-Related Quality of Life in Adult Patients with Idiopathic Inflammatory Myopathies.Integrated classification of inflammatory myopathies.Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.

P2860

Q24186948-BE4403B9-27A1-46FC-AB76-E67CA6064DEE Q26744554-5F09B652-B10F-4108-A4F0-F03899A91F57 Q26744705-17ABF147-D0A0-4A2B-8FCA-A893559D7A8E Q26786571-EBC1BC6A-CBC2-4F61-A093-E79354155E65 Q26798209-1727500B-73FB-4DDF-8C80-2D464D9A7F90 Q26829906-5201868B-6FA2-46CC-9EC8-3817BB6D69BE Q27324564-FEFE7E8E-A53F-4B53-A98E-61083D5BCA8C Q33569443-7D3D9B2E-910F-4972-9966-C1C36A8A1CF4 Q33646319-9872ACDB-7E4F-456D-A800-B7FB026F9836 Q33753870-ED1194FD-F967-439A-9C20-C9197E20A880 Q33902416-068D0234-89D5-4232-BD97-A8BD41E24B20 Q34519540-8D1994C3-BC40-49B4-910A-D656B77472DA Q34591787-13995CA9-72A6-44B2-A945-089879A5C07F Q34675925-84891F1A-2FF5-4A07-A87B-10CD9381EBCC Q35110718-5703565B-0A74-48B8-9010-8B0DD8A6E8DE Q35213944-55E2457A-5F97-4C9C-BFFD-0258613FB9D4 Q36424500-C6E1FDFC-2DCB-46D6-8886-B9F4FAA35EBC Q36575286-253CBD7F-798A-44DA-AF54-73FA591D980C Q36906852-888781B5-92B4-4627-9CA1-9D6179E2A027 Q37267141-323132D4-C792-4E40-8CCC-62D1398A4C8D Q37368405-D1F185B3-F54D-4A4E-85B6-53A5B3C5E5AC Q37400774-A8D108CC-009C-4DD6-96A3-8CB097728524 Q37421042-0C96ACBA-230D-46A4-A066-A5CFF62C134C Q37610500-8C758DE9-914C-42E2-9E20-6B4207EB9492 Q38093096-3C4AB1B2-24AD-4E00-BE14-7A3189493268 Q38131849-3D00EB78-D2E6-426D-AADF-1328FF5B9AA3 Q38220161-97141BCF-96E4-45D7-8B28-55B30279F3ED Q38296485-09FAB1FE-F717-487B-B0F4-9E8F944AC431 Q38314711-5AB6D0D5-D306-44C7-8E20-99319E208303 Q38495457-D8DD5E2B-9D68-4C10-8F48-D3125FFA02C7 Q38569863-F12FA1AE-ADC6-4B3F-B3C3-F1CD01D842BD Q38645740-392F1520-F6AC-4776-80BA-873A04FF0D3D Q38711585-A5A42AA5-EBF9-4D2A-A615-9E3252D15F2F Q38785478-5D3FBFA2-0CF2-45F1-A81F-918AC5C8B61E Q38792371-8E3869D7-8203-47BB-95E5-CE51C4194338 Q38793315-314733B3-4B97-411A-93EC-94BAB0149B91 Q38999120-A7EE958C-7CBC-4150-84E4-05171D833ED3 Q39001637-9384BF60-2F46-412E-B654-E712DBB1321B Q39027323-63583453-4DC3-45A9-9EFB-B029CA5BEF51 Q39382516-3B545D71-CFDA-4565-94E1-4C9C7826EB9A

P2860

Long-term observational study of sporadic inclusion body myositis.

http://www.wikidata.org/entity/Q39698054

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Long-term observational study of sporadic inclusion body myositis.

@en

Long-term observational study of sporadic inclusion body myositis.

@nl

type

label

Long-term observational study of sporadic inclusion body myositis.

@en

Long-term observational study of sporadic inclusion body myositis.

@nl

prefLabel

Long-term observational study of sporadic inclusion body myositis.

@en

Long-term observational study of sporadic inclusion body myositis.

@nl

P1433

Q39698054-4DCBCD68-C8BE-4236-9BA5-215B7DA6F6DE

P1476

Q39698054-5BED53C6-A2DC-4BA5-8C9E-06DB92326DAE

P2093

Q39698054-01755168-C43E-4258-9EF3-91D2BD03084D

Q39698054-09EECE06-B84E-45CB-B232-323320C551E2

Q39698054-14BA1A8A-4068-4F74-85DD-2DC41CE92F98

Q39698054-2CD8C14E-0259-40F0-974F-C890CA51F720

Q39698054-5A0B3DF5-92AC-41FF-B32A-CAE218DFB323

Q39698054-8143E4AC-7821-4E24-847B-C7B1F0AC021E

Q39698054-90DF8229-F932-48C8-BD7F-C011D139A5EE

Q39698054-968173BC-DE29-443B-B4CF-8B09BBFB6FE1

Q39698054-A7789E80-8EDA-432B-A9F5-97367780F234

Q39698054-D3F2CE78-796F-484C-8C02-63B29E3F19AF

P2860

Q39698054-1109AA02-CDF6-4FF9-BC83-3468EAF79D87

Q39698054-1C107F3B-378B-4702-B384-FC619723BDD3

Q39698054-20286EB2-8E61-416F-A339-9355B120CC26

Q39698054-22AB91E1-09A9-4E82-A213-4998B834E63A

Q39698054-268075C5-08BF-42FC-A043-1EEFC3821B90

Q39698054-2F48DCBC-411D-4263-827D-F3B63E12A2B5

Q39698054-3E5AA79C-A268-4AA5-83A4-D04ABACFE0B1

Q39698054-4A6E19A7-08FC-4A26-A4E6-6C59AEEE34FC

Q39698054-52ED16E4-6AE2-443E-8B25-E60B256E38FE

Q39698054-54E87BC6-E11E-411F-9A38-5A4883D1979C

P304

Q39698054-30CBD9D3-1E2B-4697-ACF4-216B6FEC9B80

P31

Q39698054-1B07F061-A441-43FC-A2F6-2BAF7B3E2ED8

P356

Q39698054-C7C8C34E-E6A6-4A58-894F-4AF6D910156D

P407

Q39698054-E4BCB5C8-6E89-49E9-BB07-42AF4436862E

P433

Q39698054-86CBE474-A240-4259-843C-916FD860391C

P478

Q39698054-60843062-71C5-4659-B984-2848A3A814FD

P50

Q39698054-D9D20186-D6D7-485B-A469-0D5ADED55CEB

P577

Q39698054-2DA66823-BA79-4382-A026-EA9DF9E61297

P5875

Q39698054-2D690B4E-73C5-4EA5-8F1B-250035599DF9

P698

Q39698054-9F1085E1-4E45-4F56-99CE-9A5D8BD0C92D

P356

P1433

P1476

Long-term observational study of sporadic inclusion body myositis

@en

P2093

Bruno Eymard

http://www.w3.org/2001/XMLSchema#string

David Hilton-Jones

http://www.w3.org/2001/XMLSchema#string

Jane Freebody

http://www.w3.org/2001/XMLSchema#string

Marguerite Guiguet

http://www.w3.org/2001/XMLSchema#string

Maria Isabel Leite

http://www.w3.org/2001/XMLSchema#string

Odile Dubourg

http://www.w3.org/2001/XMLSchema#string

Olivier Benveniste

http://www.w3.org/2001/XMLSchema#string

Serge Herson

http://www.w3.org/2001/XMLSchema#string

Stefen Brady

http://www.w3.org/2001/XMLSchema#string

Tanya Stojkovic

http://www.w3.org/2001/XMLSchema#string

P2860

Steroid myopathy in connective tissue disease

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.

Inclusion body myositis and myopathies.

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies.

Inclusion body myositis: review of recent literature.

Fraction of normal remaining life span: a new method for expressing survival in cancer.

Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains.

P304

3176-3184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWR213

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 11

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51714456

http://www.w3.org/2001/XMLSchema#string

P698

21994327

http://www.w3.org/2001/XMLSchema#string